Maraviroc

A cyclohexane and triazole derivative that acts as an antagonist of the CCR5 RECEPTOR. It prevents infection by HIV-1 virus strains which use CCR5 as a co-receptor for membrane fusion and cellular entry.

Also Known As:

4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; Selzentry; UK-427,857; UK-427857; UK 427,857; UK 427857; UK427,857; UK427857; Cyclohexanecarboxamide, 4,4-difluoro-N-((1S)-3-((3-exo)-3-(3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)-

Networked: 333 relevant articles (28 outcomes, 68 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Heera, Jayvant: 13 articles (01/2019 - 03/2010)
2.	Francisci, Daniela: 8 articles (04/2019 - 01/2013)
3.	van der Ryst, Elna: 8 articles (06/2015 - 01/2005)
4.	Mayer, Howard: 8 articles (12/2010 - 10/2008)
5.	Gulick, Roy M: 7 articles (01/2022 - 10/2008)
6.	Fätkenheuer, Gerd: 7 articles (01/2017 - 10/2008)
7.	Goodrich, James: 7 articles (12/2010 - 10/2008)
8.	Westby, Mike: 7 articles (03/2010 - 01/2005)
9.	Moreno, Santiago: 6 articles (12/2020 - 12/2010)
10.	Pérez-Martínez, Laura: 6 articles (01/2020 - 01/2013)

Related Diseases

1.	HIV Infections (HIV Infection) 12/01/2015 - "We used bone marrow/liver/thymus (BLT) humanized mice to establish the effect of semen on vaginal HIV infection and on the efficacy of topically applied maraviroc. " 01/01/2012 - "This article reviews the safety and efficacy of maraviroc in the treatment of HIV infection. " 09/19/2017 - "Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial." 01/15/2017 - "Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)." 11/01/2016 - "Maraviroc concentrations in blood, secretions (vaginal, urethral, oral, and rectal), and tissue (vaginal and rectal) were measured, and ex vivo challenge was performed in 54 healthy volunteers to study protection from HIV infection. "
2.	Infections 03/31/2007 - "Maraviroc is only effective against CCR5-tropic virus, which predominates throughout infection but is more common in patients at the early asymptomatic stage of infection." 01/01/2020 - "We can draw two inferences from our observations: (1) to enhance the utility of Maraviroc in chronic HIV subtype C infections in Africa, prior virus co-receptor determination is needed; (2) on the flip side, research on the efficacy of CXCR4 antagonists for HIV-1-C infections is encouraged. " 12/15/2010 - "Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2." 12/01/2016 - "The MAIN (Maraviroc in HIV Acute INfection) study was a randomized open-label clinical trial (EUDRACT number: 2008-007004-29) which enrolled 29 patients with PHI. " 10/01/2014 - "In combination studies, R4.0, CCL5, and maraviroc exhibited concomitant interactions with CCR5 and promoted synergic inhibition of HIV-1 in acute-infection assays. "
3.	Inflammation (Inflammations) 07/01/2015 - "Combinations with maraviroc were effective in reducing inflammation, but data about immunological recovery are conflicting. " 10/06/2010 - "Maraviroc-treated patients had earlier, modest decreases in certain markers of immune activation and inflammation, although in this small study, many of the differences were not statistically significant. " 06/01/2014 - "Potential anti-inflammatory effects of maraviroc in HIV-positive patients: a pilot study of inflammation, endothelial dysfunction, and coagulation markers." 03/01/2013 - "These results support the additional immunological effects of CCR5 blockade and suggest that maraviroc might have potential capacity to inhibit HIV-associated chronic inflammation and activation, both by directly affecting T cell activation and by reducing entrapment of lymphocytes in lymph nodes." 01/01/2023 - "Maraviroc may reduce hepatic inflammation in people with HIV and non-alcoholic fatty liver disease (HIV-NAFLD) through CCR5-receptor antagonism, which warrants further exploration. "
4.	Non-alcoholic Fatty Liver Disease 07/01/2014 - "Maraviroc ameliorates hepatic steatosis in an experimental model of NAFLD." 07/01/2014 - "Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD)." 01/01/2023 - "Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease." 07/01/2014 - "The objective of this study was to examine the effects of maraviroc, a CCR5 antagonist, on liver pathology in a NAFLD mouse model. " 01/01/2023 - "This feasibility study provides preliminary evidence of maraviroc safety amongst people with HIV-NAFLD, and acceptable recruitment, retention, and adherence rates. "
5.	Wounds and Injuries (Trauma) 01/01/2016 - "Maraviroc treatment also decreased lung tissue damage as compared to the vehicle-treated trauma-hemorrhaged rats. " 01/01/2016 - "These parameters significantly improved in the maraviroc-treated rats subjected to trauma-hemorrhage. " 01/01/2013 - "These parameters were significantly improved in the maraviroc-treated rats subjected to trauma-hemorrhage. " 01/01/2016 - "The aim of this study was to investigate whether PPARγ plays an important role in maraviroc-mediated lung protection following trauma-hemorrhage. " 01/01/2016 - "These results suggest that PPARγ might play a key role in maraviroc-mediated lung protection following trauma-hemorrhage. "

Related Drugs and Biologics

1.	CCR5 Receptors (CCR5 Receptor)
2.	Ritonavir (Norvir)
3.	dolutegravir
4.	Raltegravir Potassium
5.	Methotrexate (Mexate)
6.	Tacrolimus (Prograf)
7.	Protease Inhibitors (Protease Inhibitor)
8.	Atazanavir Sulfate (Reyataz)
9.	Chemokine CCL5
10.	Pravastatin (Pravachol)

Related Therapies and Procedures

1.	Therapeutics
2.	Transplantation
3.	Oral Administration
4.	Highly Active Antiretroviral Therapy (HAART)
5.	Hematopoietic Stem Cell Mobilization